BOOK
Colon Cancer, An Issue of Surgical Oncology Clinics of North America, E-Book
(2018)
Additional Information
Book Details
Abstract
This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Mark Arnold, is devoted to Colon Cancer. Dr. Arnold has assembled expert authors to review the following topics: Chemotherapy for Colon Cancer; Colon Cancer: What We Eat; Colon Cancer: Inflammatory Associated Cancer; Colon Cancer: The Imaging Conundrum; Minimally Invasive Surgical Approaches to Colon Cancer; Population Screening for Hereditary Colorectal Cancer; The Economics of Colon Cancer; Clinical Trials in Colon Cancer; Advanced Colonoscopic Techniques; Surgical Treatment of Metastatic Disease; The Metastatic Lymph Node; and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Colon Cancer | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Foreword: Colon Cancer | vii | ||
| Preface: Colon Cancer: The Road Traveled | vii | ||
| Systemic Therapy for Colon Cancer | vii | ||
| Colon Cancer: What We Eat | vii | ||
| Colon Cancer: Inflammation-Associated Cancer | vii | ||
| Colorectal Cancer: Imaging Conundrums | viii | ||
| Minimally Invasive Surgical Approaches to Colon Cancer | viii | ||
| Population Screening for Hereditary Colorectal Cancer | viii | ||
| The Economics of Colon Cancer | viii | ||
| Clinical Trials and Progress in Metastatic Colon Cancer | ix | ||
| Maximizing the Effectiveness of Colonoscopy in the Prevention of Colorectal Cancer | ix | ||
| Surgical Treatment of Metastatic Colorectal Cancer | ix | ||
| Lymph Node Metastasis in Colorectal Cancer | ix | ||
| SURGICAL ONCOLOGY\rCLINICS OF NORTH AMERICA\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| July 2018 | xi | ||
| October 2018 | xi | ||
| January 2019 | xi | ||
| RECENT ISSUES | xi | ||
| January 2018 | xi | ||
| October 2017 | xi | ||
| July 2017 | xi | ||
| Foreword: Colon Cancer\r | xiii | ||
| Preface:\rColon Cancer: The Road Traveled | xv | ||
| REFERENCES | xvii | ||
| Systemic Therapy for Colon Cancer | 235 | ||
| Key points | 235 | ||
| INTRODUCTION | 235 | ||
| LOCALLY ADVANCED COLON CANCER AND ADJUVANT CHEMOTHERAPY | 236 | ||
| Adjuvant Therapy for Stage II Colon Cancer | 236 | ||
| Microsatellite Instability High and Stage II Colon Cancer | 236 | ||
| High-Risk Features in Stage II Colon Cancer | 237 | ||
| Adjuvant Therapy for Stage III Colon Cancer | 237 | ||
| 3 Versus 6 Months of FOLFOX for Stage III Colon Cancer | 237 | ||
| METASTATIC COLORECTAL CANCER | 237 | ||
| First- and Second-Line Chemotherapy | 237 | ||
| Antibody Therapy Targeting Vascular Endothelial Growth Factor Pathway | 238 | ||
| Antibody Therapy Targeting Epidermal Growth Factor Receptor Pathway | 239 | ||
| Refractory Colon Cancer | 240 | ||
| Immunotherapy for Microsatellite Instability-High Cancers | 240 | ||
| REFERENCES | 241 | ||
| Colon Cancer | 243 | ||
| Key points | 243 | ||
| INTRODUCTION | 243 | ||
| MATERIALS AND METHODS | 244 | ||
| Red Meat and Processed Meat | 245 | ||
| Fish | 246 | ||
| Fibers from All Sources | 249 | ||
| Fiber from Whole Grains and Cereals | 252 | ||
| Fruit and Vegetables | 252 | ||
| Vitamins and Minerals | 255 | ||
| Coffee and Tea | 259 | ||
| SUMMARY/DISCUSSION | 259 | ||
| REFERENCES | 259 | ||
| Colon Cancer | 269 | ||
| Key points | 269 | ||
| INTRODUCTION | 269 | ||
| EPIDEMIOLOGY | 270 | ||
| Risk Factors for Developing Carcinoma in Patients with Inflammatory Bowel Disease | 270 | ||
| Age at onset of disease | 270 | ||
| Duration of disease | 271 | ||
| Anatomic extent of disease | 271 | ||
| Histologic changes versus macroscopic changes | 271 | ||
| Backwash ileitis and the risk of colorectal cancer | 271 | ||
| Primary sclerosing cholangitis | 271 | ||
| Family history of colorectal cancer | 272 | ||
| Other factors and special considerations | 272 | ||
| PATHOGENESIS | 272 | ||
| SURVEILLANCE | 274 | ||
| Visible Versus Invisible Lesions and White Light Endoscopy Versus Chromoendoscopy | 275 | ||
| Dysplasia in Inflammatory Bowel Disease | 275 | ||
| Type of Lesions Detected Endoscopically | 275 | ||
| Histologic Interpretation | 276 | ||
| Surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Inflammatory Bowel Disease Patients | 276 | ||
| International consensus recommendations: Surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Infla ... | 276 | ||
| Classification (nomenclature) of dysplasia in inflammatory bowel disease | 276 | ||
| MANAGEMENT OF COLITIS-ASSOCIATED CANCER | 277 | ||
| Management of Endoscopically Visible Lesions | 277 | ||
| Pouch Surveillance | 278 | ||
| Surgical Management | 278 | ||
| SPECIAL CONSIDERATIONS | 278 | ||
| Mucosectomy Versus Stapled Anastomosis and Keeping the Anal Transitional Zone | 278 | ||
| Rectal Cancer in Patients with Colitis | 279 | ||
| Risk of Cancer After Colectomy | 280 | ||
| PERSONALIZED MEDICINE FOR COLITIS-ASSOCIATED CANCER: 3-DIMENSIONAL HUMAN MODELS | 281 | ||
| Research Summary | 282 | ||
| FUTURE TREATMENT STRATEGIES | 282 | ||
| ACKNOWLEDGMENTS | 282 | ||
| REFERENCES | 282 | ||
| Colorectal Cancer: | 289 | ||
| Key points | 289 | ||
| INTRODUCTION | 289 | ||
| THE CONUNDRUM OF SENSITIVITY: TRANSLATING LESION DETECTABILITY FROM THE READING ROOM INTO THE OPERATING ROOM | 291 | ||
| THE CONUNDRUM OF SPECIFICITY: THE CONFLICT BETWEEN LESION DETECTABILITY AND SENSITIVITY | 294 | ||
| A SOLUTION TO BOTH CONUNDRUMS: INTRAOPERATIVE GUIDANCE | 295 | ||
| REFERENCES | 296 | ||
| Minimally Invasive Surgical Approaches to Colon Cancer | 303 | ||
| Key points | 303 | ||
| INTRODUCTION | 303 | ||
| EVOLUTION OF MINIMALLY INVASIVE SURGICAL TECHNIQUES IN COLON CANCER | 304 | ||
| PATIENT SELECTION IN MINIMALLY INVASIVE SURGERY FOR COLON CANCER | 305 | ||
| ADVANTAGES OF MINIMALLY INVASIVE SURGERY IN COLON CANCER | 306 | ||
| RIGHT COLON CANCER | 306 | ||
| Surgical Techniques | 306 | ||
| Laparoscopic right colectomy | 306 | ||
| Single-incision surgery for right colon cancer | 308 | ||
| Robotic right colectomy | 308 | ||
| Extent of Resection | 308 | ||
| LEFT COLON CANCER | 309 | ||
| Surgical Techniques | 309 | ||
| Multiport laparoscopic left colectomy | 309 | ||
| Releasing the splenic flexure | 309 | ||
| Positioning the small bowel | 310 | ||
| Transection of the inferior mesenteric artery and the inferior mesenteric vein | 311 | ||
| Mobilization of the colon | 311 | ||
| Transection of the mesorectum | 311 | ||
| Transection of the rectum | 311 | ||
| Exteriorization of the specimen | 312 | ||
| The anastomosis | 312 | ||
| Closing | 312 | ||
| Hand-assisted laparoscopic left colectomy | 312 | ||
| Single-incision laparoscopic left colectomy | 313 | ||
| Robotic left colectomy | 313 | ||
| Special Considerations | 314 | ||
| OUTCOMES | 314 | ||
| SUMMARY | 315 | ||
| REFERENCES | 315 | ||
| Population Screening for Hereditary Colorectal Cancer | 319 | ||
| Key points | 319 | ||
| INTRODUCTION | 319 | ||
| LYNCH SYNDROME | 320 | ||
| UNIVERSAL TUMOR SCREENING FOR LYNCH SYNDROME | 320 | ||
| CANCER GENETIC TESTING IN UNSELECTED COLORECTAL CANCER PATIENTS | 322 | ||
| IMPLICATIONS | 322 | ||
| SUMMARY | 324 | ||
| REFERENCES | 324 | ||
| The Economics of Colon Cancer | 327 | ||
| Key points | 327 | ||
| INTRODUCTION | 327 | ||
| ECONOMIC BURDEN OF CANCER | 328 | ||
| ECONOMIC COST OF COLORECTAL CANCER | 329 | ||
| FINANCIAL BURDEN ON CANCERS SURVIVORS | 329 | ||
| FINANCIAL BURDEN OF CANCER SURVIVORS: ADOLESCENTS AND YOUNG ADULTS | 330 | ||
| ECONOMIC COST OF MEDICAL ONCOLOGY | 330 | ||
| HIGH COST OF CANCER DRUGS | 332 | ||
| Medicare’s Average Sales Price | 332 | ||
| Policies That Mandate Cancer Drug Coverage | 333 | ||
| Impact of Coverage Expansion | 333 | ||
| Role of Genomic Sequencing | 333 | ||
| EARLY COLON CANCER MEASURES, QUALITY, VALUE, AND COST | 333 | ||
| Value | 334 | ||
| Value of Cancer Care in the United States | 335 | ||
| COLORECTAL CANCER SCREENING HEALTH LITERACY | 335 | ||
| Heath Care Access and Colorectal Cancer Screening | 336 | ||
| SURGICAL COST OF COLON CANCER | 337 | ||
| COST EFFECTIVENESS OF LAPAROSCOPIC VERSUS ROBOTIC VERSUS OPEN RESECTION | 337 | ||
| Hospital Duration of Stay and Readmission Rates | 338 | ||
| Cost of Readmission | 339 | ||
| Post Acute Care Spending After Surgery | 340 | ||
| END-OF-LIFE SPENDING | 341 | ||
| SUMMARY | 345 | ||
| REFERENCES | 345 | ||
| Clinical Trials and Progress in Metastatic Colon Cancer | 349 | ||
| Key points | 349 | ||
| INTRODUCTION | 349 | ||
| MUTATIONS IN THE RAS PATHWAY AND THEIR IMPLICATIONS ON CHOICE OF THERAPY | 350 | ||
| TUMORS | 353 | ||
| TARGETING THE AMPLIFIED HER2 PATHWAY | 354 | ||
| OTHER TARGETS | 355 | ||
| THE ROLE OF IMMUNOTHERAPY | 356 | ||
| Microsatellite Instability High Disease | 356 | ||
| Microsatellite Instability Low Disease or Stable Disease | 357 | ||
| SUMMARY | 358 | ||
| REFERENCES | 359 | ||
| Maximizing the Effectiveness of Colonoscopy in the Prevention of Colorectal Cancer | 367 | ||
| Key points | 367 | ||
| EFFECTIVENESS OF COLONOSCOPY FOR COLORECTAL CANCER PREVENTION | 367 | ||
| INTERVAL COLORECTAL CANCER | 368 | ||
| INCREASING THE ADENOMA DETECTION RATE | 368 | ||
| ASSISTIVE DEVICES | 370 | ||
| POLYPECTOMY | 371 | ||
| ADVANCED POLYPECTOMY | 372 | ||
| REFERENCES | 373 | ||
| Surgical Treatment of Metastatic Colorectal Cancer | 377 | ||
| Key points | 377 | ||
| MANAGEMENT OF METASTATIC COLORECTAL CANCER | 377 | ||
| Genetic Mutation and Sites of Metastasis | 378 | ||
| Perioperative Chemotherapy for Liver Metastases | 379 | ||
| Treatment Order with Synchronous Metastases | 380 | ||
| SURGICAL MANAGEMENT OF HEPATIC METASTASES | 382 | ||
| Indications for Resection and Outcomes | 382 | ||
| Technical Strategies for Resection | 383 | ||
| Adjuncts to Resection | 385 | ||
| SURGICAL MANAGEMENT OF PERITONEAL METASTASES | 387 | ||
| Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | 387 | ||
| Patient Selection and Outcomes | 388 | ||
| SURGICAL MANAGEMENT OF PULMONARY METASTASIS | 390 | ||
| SUMMARY | 391 | ||
| REFERENCES | 391 | ||
| Lymph Node Metastasis in Colorectal Cancer | 401 | ||
| Key points | 401 | ||
| INTRODUCTION | 401 | ||
| CONTENT | 402 | ||
| American Joint Committee on Cancer Lymph Node Staging | 402 | ||
| Required number of total lymph nodes | 402 | ||
| American Joint Committee on Cancer N staging definition | 402 | ||
| The impact of N category on prognostic stage groups | 403 | ||
| Tumor Deposit | 403 | ||
| Tumor deposit definition evolution | 403 | ||
| Prognostic significance of tumor deposit | 405 | ||
| Interpretation challenges | 406 | ||
| Tumor deposit versus discontinuous tumor spread | 407 | ||
| Tumor deposit versus totally replaced lymph node | 407 | ||
| Tumor deposit versus venous invasion | 407 | ||
| Isolated Tumor Cells and Micrometastases | 408 | ||
| Lymph Node Ratio | 408 | ||
| Neoadjuvant Treatment Effect in Rectal Cancer | 409 | ||
| Required number of total lymph nodes | 409 | ||
| Acellular mucin | 410 | ||
| Regression assessment after neoadjuvant therapy | 410 | ||
| SUMMARY | 410 | ||
| ACKNOWLEDGMENTS | 410 | ||
| REFERENCES | 410 |